Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of adrenal genes regulated in a potassium-dependent manner.
Dierks A, Lichtenauer UD, Sackmann S, Spyroglou A, Shapiro I, Geyer M, Manonopoulou J, Reincke M, Hantel C, Beuschlein F. Dierks A, et al. Among authors: sackmann s. J Mol Endocrinol. 2010 Oct;45(4):193-206. doi: 10.1677/JME-09-0171. Epub 2010 Jul 20. J Mol Endocrinol. 2010. PMID: 20647392
Treatment of endometrial cancer from 2000 to 2020 in Germany: a retrospective population based cohort study.
Papathemelis T, Ortmann O, Kohl C, Neuser P, Tol KK, Klinkhammer-Schalke M, Ugocsai P, Walter CB, Rottmann M, Real C, Justenhoven C, Robers G, Schneider C, Gerken M, Sackmann A, Kim-Wanner SZ. Papathemelis T, et al. J Cancer Res Clin Oncol. 2024 May 27;150(5):279. doi: 10.1007/s00432-024-05772-9. J Cancer Res Clin Oncol. 2024. PMID: 38802682 Free PMC article.
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
Somatostatin slows Aβ plaque deposition in aged APPNL-F/NL-F mice by blocking Aβ aggregation.
Williams D, Yan BQ, Wang H, Negm L, Sackmann C, Verkuyl C, Rezai-Stevens V, Eid S, Vediya N, Sato C, Watts JC, Wille H, Schmitt-Ulms G. Williams D, et al. Sci Rep. 2023 Feb 9;13(1):2337. doi: 10.1038/s41598-023-29559-z. Sci Rep. 2023. PMID: 36759538 Free PMC article.
The neuroendocrine peptide somatostatin (SST) has long been thought of as influencing the deposition of the amyloid beta peptide (Abeta) in Alzheimer's disease (AD). Missing have been in vivo data in a relevant Abeta amyloidosis model. ...
The neuroendocrine peptide somatostatin (SST) has long been thought of as influencing the deposition of the amyloid beta peptide (Abeta) in …
Function follows form: how the structure of neurons determines cortical network activity : Comment on: Hodapp A, Kaiser ME, Thome C, Ding L, Rozov A, Klumpp M, Stevens N, Stingl M, Sackmann T, Lehmann N, Draguhn A, Burgalossi A, Engelhardt M, Both M (2022) Dendritic axon origin enables information gating by perisomatic inhibition in pyramidal neurons. Science 377:1448-1452.
Draguhn A, Both M. Draguhn A, et al. Pflugers Arch. 2023 Mar;475(3):285-287. doi: 10.1007/s00424-022-02776-7. Epub 2022 Dec 3. Pflugers Arch. 2023. PMID: 36462030 Free PMC article. No abstract available.
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M. Stratmann JA, et al. J Cancer Res Clin Oncol. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22. J Cancer Res Clin Oncol. 2018. PMID: 30244389
Disease control rate did not correlate with clinical characteristics and was independent of number as well as type of the previous therapy line(s). Estimated progression-free survival was 10.1 months (95% CI 9.2-11.0 months). Osimertinib showed a favorable toxicity profile …
Disease control rate did not correlate with clinical characteristics and was independent of number as well as type of the previous therapy l …
73 results